(NASDAQ:WLDS),(NASDAQ:WLDSW), Yokneam Illit, Israel, Sept. 12, 2025 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) (the “Company” or “Wearable Devices”), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of […]

(NasdaqGM:PRE), 1st Half revenue grew 452.1% to $32.3 million YoY IM8 achieved $5.9 million revenue in August 2025, representing a CAGR1 of over 3,100% Prenetics increases FY2025 revenue guidance range of $85 – $100 million Prenetics provides update on Bitcoin Treasury, adding a total of 228 Bitcoin, and accumulating 1 BTC daily Prenetics to achieve

(NASDAQ:ALXO), Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company's Board of Directors and will step down from the Board to join ALX as Interim Chief Medical Officer Alan Sandler, M.D. resigns as Chief Medical Officer and will return to his

(Other OTC:REED),(OTC US:REED), NORWALK, Conn., Sept. 12, 2025 (GLOBE NEWSWIRE) — Reed's, Inc. (OTCQX: REED) (“Reed's” or the “Company”), owner of the nation's leading portfolio of handcrafted, natural ginger beverages, today announced a series of organizational and leadership updates aimed to enhance its operational efficiency and position the Company for long-term success. Following a careful

(NASDAQ:BDRX), September 12, 2025 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months

House of Doge Official Dogecoin Treasury Partner CleanCore Acquires Over 500 Million DOGE on Accelerated Path to 1 Billion Significant milestone marks the halfway point towards the Company's goal to acquire up to 1 billion DOGE within 30 days GlobeNewswire September 12, 2025 MIAMI, Sept. 12, 2025 (GLOBE NEWSWIRE) — House of Doge, the official

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies GlobeNewswire September 12, 2025 HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire September 12, 2025 JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”), today announced that it has received a written notice (the “Notice”), dated September 11, 2025, from the

Reed's Announces Organizational and Leadership Updates to Support Growth and Optimization Initiatives Appoints Veteran Luxury and Spirits Marketer Tina Reejsinghani as CMO to Lead Next Phase of Brand Growth GlobeNewswire September 12, 2025 NORWALK, Conn., Sept. 12, 2025 (GLOBE NEWSWIRE) — Reed's, Inc. (OTCQX: REED) (“Reed's” or the “Company”), owner of the nation's leading portfolio

Interim results for the six months ended June 30, 2025 GlobeNewswire September 12, 2025 September 12, 2025 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with